Leukaemia vs Lymphoma — Clinical Trial Comparison
Leukaemia
Cancer of blood-forming tissues and bone marrow
VS
Lymphoma
Cancer of the lymphatic system (Hodgkin and Non-Hodgkin)
Leukaemia and lymphoma are both blood cancers but differ fundamentally in biology, presentation, and treatment. Both have been at the forefront of breakthrough therapies — CAR-T cell therapy was first approved for blood cancers, and both benefit from rapidly expanding precision medicine.
Key Differences at a Glance
| Feature | Leukaemia | Lymphoma |
|---|---|---|
| Primary symptoms | Fatigue, infections, bruising, bone pain, swollen spleen | Swollen lymph nodes, night sweats, unexplained weight loss, fatigue |
| Common subtypes | AML, ALL, CML, CLL, Hairy cell, T-cell | DLBCL, follicular, Hodgkin, mantle cell, Burkitt, T-cell, marginal zone |
| Diagnostic method | Blood tests, bone marrow biopsy, flow cytometry, cytogenetics | Lymph node biopsy, PET-CT, blood tests, bone marrow, molecular profiling |
| Key distinction | Primarily bone marrow and blood | Primarily lymph nodes and lymphatic tissue |
| Curability | Variable: some curable (ALL in children), others manageable (CML, CLL) | Highly curable (Hodgkin ~85%), variable (indolent NHL) |
| Prevalence in UK | ~10,000 new cases/year | ~14,000 new cases/year |
Clinical Trial Availability
| Trial Aspect | Leukaemia | Lymphoma |
|---|---|---|
| UK trials actively recruiting | 50-80 studies | 60-100 studies |
| Most common trial phase | Phase 1-3 | Phase 1-3 |
| Top interventions tested | Targeted therapies, immunotherapy, CAR-T, stem cell transplant | CAR-T, bispecific antibodies, ADCs, checkpoint inhibitors, targeted therapy |
| CAR-T trials | Active (ALL, AML emerging) | Major focus (DLBCL, follicular, mantle cell) |
| Targeted therapy trials | TKIs (CML), BCL-2 inhibitors, IDH inhibitors, FLT3 inhibitors | BTK inhibitors, BCL-2 inhibitors, PI3K inhibitors, EZH2 inhibitors |
| Stem cell transplant trials | Major focus (allogeneic) | Important role (autologous and allogeneic) |
Exciting Emerging Treatments
Leukaemia Trials
- CAR-T cell therapy for AML — extending CAR-T beyond lymphoma and ALL
- Bispecific antibodies — engaging T-cells against leukaemia cells
- FLT3 inhibitors — targeted therapy for FLT3-mutated AML
- IDH1/2 inhibitors — precision medicine for IDH-mutant AML
- Menin inhibitors — novel target for KMT2A-rearranged and NPM1-mutant leukaemia
- MRD-guided therapy — treatment decisions based on minimal residual disease
Lymphoma Trials
- Next-generation CAR-T — faster manufacturing, better persistence, reduced toxicity
- Bispecific T-cell engagers (BiTEs) — off-the-shelf alternative to CAR-T
- Antibody-drug conjugates — polatuzumab, loncastuximab for NHL
- BTK inhibitor next-gen — pirtobrutinib for BTK-inhibitor-resistant disease
- Checkpoint inhibitor combinations — for Hodgkin and primary mediastinal lymphoma
- Personalised vaccine approaches — neoantigen vaccines for lymphoma
💡 Not sure which trials you qualify for?
Use our Smart Matcher to answer a few questions about your condition and we'll find the most relevant trials for your specific situation — free, instant results.
Eligibility Differences
Leukaemia Trial Criteria
- Specific leukaemia subtype required (AML trials exclude CML, etc.)
- Cytogenetic and molecular profiling often mandatory (FLT3, IDH, NPM1, KMT2A)
- Performance status and organ function thresholds for intensive therapy trials
- Prior treatment history critical (newly diagnosed vs relapsed/refractory)
- Age is a major factor — some trials separate paediatric and adult populations
Lymphoma Trial Criteria
- Histological subtype confirmed by expert pathology review
- Ann Arbor staging and IPI score determine appropriateness
- Relapsed/refractory status with documented prior therapies required
- CAR-T trials: specific prior treatment requirements and bridging therapy considerations
- PET-CT response assessment increasingly used for trial eligibility
Frequently Asked Questions
Can I join a clinical trial if I have both Leukaemia and Lymphoma?
It depends on the specific trial. Many trials allow comorbid conditions as long as the primary condition being studied is clearly dominant. Some trials explicitly exclude patients with significant overlapping conditions. Always check the eligibility criteria carefully and discuss with both the trial team and your specialist.
Which condition has more clinical trials available in the UK?
Both Leukaemia and Lymphoma have robust research pipelines with new studies opening regularly. The number of trials varies over time as new studies launch and others complete. Check our condition pages for the most current trial availability.
What should I consider when choosing between trials for these conditions?
Consider which condition impacts your quality of life most, what treatments you've already tried, the trial phase (earlier phases are more experimental), the time commitment involved, and whether the trial offers access to treatments not otherwise available. Your specialist can help you prioritise.